Immunomonitoring

The Cancer Immunomonitoring Platform (CIP), located on the campus of the Institut Paoli-Calmettes, is part of the Marseille Cancer Research Centre and is affiliated with the IPC, Inserm, CNRS and Aix-Marseille University. IBiSA-accredited since 2008, ISO 9001 (2015) and NF X50-900 (2016) certified, the platform is open to the academic and industrial scientific community as part of collaborations and/or project services related to oncology and immunology.

Skills and expertise:

• Analysis of the tumour microenvironment as part of fundamental and preclinical research projects on experimental models and in humans
• Identification of the mechanisms involved in the appearance of cancer-related alterations in innate and adaptive immunity
• Preclinical development of biotherapies
• Development and validation of biomarkers (diagnostic, prognostic and predictive of response and toxicity) in haemopathies and solid tumours treated by immunotherapy
• Monitoring anti-tumour responses under immunotherapy (monoclonal antibodies, vaccination, transplantation)
  • Mapping of immune populations and therapeutic targets
  • Monitoring the binding of therapeutic antibodies to immune populations after binding
  • Monitoring of the cellular state following the binding of therapeutic antibodies
  • Identification of alternative checkpoints for immunotherapy combinations
  • Elucidation of mechanisms of resistance to immunotherapies

Activities:

• Handling patient samples (blood, marrow and tissue)
• Assay of cytokines, chemokines and soluble biomarkers (ELISA, Luminex)
• RNA and/or DNA assays, extraction of RNA and/or DNA
• Reverse transcription and RQ-PCR
• Genotyping
• Plasmid production
• Single or double expansion of NK lymphocytes and Tgd lymphocytes
• 3D culture (spheroids, organoids)
• Immunofluorescence (IF) and RNAscope
• Phenotyping using multiparametric cytometry (conventional cytometry, spectral cytometry and mass cytometry) to characterise cell populations
• In vitro functional assays (cytotoxicity, proliferation, cytokine production)
• Transcriptomics, scRNAseq
• Statistical analysis (correlation between biological and clinical parameters)
• Bioinformatics analysis of high-dimensional data (machine learning)

Equipments:

• Culture room (P1, P2) with microbiological safety station (PSM)
• CO2 incubator for cell culture (Heraeus)
• Centrifuges (Thermoscientific)
• Inverted microscopes (Olympus)
• Flow cytometer: canto II (BD Biosciences)
• Mass cytometer: Helios (Standard Biotools)
• Luminex Bio-Plex 200 (Bio-Rad)
• Bioanalyser (Agilent)
• Hybridization oven (Bio-Techne)
• Spectro-fluo-photometer (proteigene)
• Various small items of equipment: gentleMACS Dissociator (Miltenyi), laboratory balance, etc.

Key Publications

CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.

S Fattori, A Le Roy, J Houacine, L Robert, R Abes, L Gorvel, S Granjeaud, MS Rouvière, A Ben Amara, N Boucherit, C Tarpin, J Pakradouni, E Charafe-Jauffret, G Houvenaeghel, E Lambaudie, F Bertucci, P Rochigneux, A Gonçalves, A Foussat, AS Chretien, D Olive. Cancer Research 2023.

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.

Demerlé C, Gorvel L, Mello M, Pastor S, Degos C, Zarubica A, Angelis F, Fiore F, Nunes JA, Malissen B, Greillier L, Guittard G, Luche H, Barlesi F, Olive D. J Immunother Cancer. 2023.

Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients.

P Rochigneux, A Lisberg, A Garcia, S Granjeaud, A Madroszyk, S Fattori, A Gonçalves, R Devillier, P Maby, N Salem, L Gorvel, B Chanez, J Gukasyan, J Caroll, J Goldman, AS Chretien, D Olive, E Garon. Clinical Cancer Research 2022.

High throughput mass cytometry staining for deep phenotyping of human NK cells (invited article).

A Ben Amara, MS Rouviere, S Fattori, J Wlosik, E Gregori, N Boucherit, PL Bernard, J Nunès, N Vey, H Luche, L Gorvel, D Olive, AS Chretien. STAR Protocols 2022.

Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation.

Gorvel L, Olive D. Semin Immunol. 2023.

High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome.

AS Chretien, R Devillier, S Granjeaud, C Cordier, C Demerle, N Salem, J Wlosik, F Orlanducci, E Gregori, M Paul, P Rochigneux, T Pagliardini, M Morey, C Fauriat, N Dulphy, A Toubert, H Luche, M Malissen, D Blaise, J Nunès, N Vey, D Olive. PNAS 2021.

Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.

De Gassart A, Le KS, Brune P, Agaugué S, Sims J, Goubard A, Castellano R, Joalland N, Scotet E, Collette Y, Valentin E, Ghigo C, Pasero C, Colazet M, Guillén J, Cano CE, Marabelle A, De Bonno J, Hoet R, Truneh A, Olive D, Frohna P. Sci Transl Med. 2021.

3D Tumor Models and Their Use for the Testing of Immunotherapies.

Boucherit N, Gorvel L, Olive D. Front Immunol. 2020.